This site is intended for health professionals only

Published on 22 September 2011

Share this story:
Twitter
LinkedIn

European Commission authorise sedative Dexdor®

teaser

The European Commission has granted centralised marketing authorisation for Dexdor® (dexmedetomidine), indicated for sedation of adult intensive care unit (ICU) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale 0 to -3).

Dexdor® (dexmedetomidine) is now licensed across all 27 countries in the European Union.

The active substance of dexdor® is dexmedetomidine, a sedative agent originated by Orion Corporation’s pharmaceutical R&D.
Dexmedetomidine is available with the brand name Precedex® in more than 30 countries outside Europe, including the USA (since 2000) and Japan (since 2004).

The distributor for the product outside Europe is Hospira, under Orion’s license.

Orion Corporation



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn